On June 9, 2025, Applied Therapeutics, Inc. held its Annual Meeting where stockholders elected a new director, ratified Ernst & Young as auditors, approved executive compensation, chose to hold future votes annually, and approved a stock consolidation plan ranging from 1-for-5 to 1-for-40. The meeting reflected active shareholder engagement and governance decisions.